对抗致病菌的新的抗毒性方法(英文教学)A new antivirulence approach against pathogenic bacteria方案说明.pptVIP

 A new antivirulence approach against pathogenic bacteria  May 2005 Sonia Escaich - President CSO Corporate overview Biopharmaceutical company specialized in antibacterial drug discovery for prevention of severe infections especially nosocomial Portfolio of intellectual property Virulence validated targets – Preclinical development of inhibitors small molecules Experienced management and RD team - Prestigious academic partnerships - 3 RD grants (ANVAR, Genhomme, BioSecurity) 20 Employees: 1 CEO/CSO, 1 director MedChem, 9 biologists/biochemists, 7 medicinal chemists (8 Ph.D,10 RAs) 2 GAs Incorporated mid-2001 - Located at Biocitech Parc, Paris (France) EUR 10.2M (USD 13M) raised since 2002 - Investors: BioAm, Axa PE, Auriga, Credit Agricole PE. MUTABILIS’ research objectives Discovery of innovative anti-virulence treatments for nosocomial infections Therapeutic molecules : Inhibition of virulence factors. Therapeutic vaccines and antibodies Background: Medical need for new anti-infective therapies Nosocomial infections (NI) occur in 2-10% of hospitalized patients (ICU, Surgery, internal medicine…) Three types of pathogens: Gram+ bacteria: 45%. Gram- bacteria: 35%. Others: 20%. Complications of nosocomial infections generate extensive hospitalization, and intensive care costs. Severe infections and sepsis can be lethal (30% cases) The increasing number of invasive procedures and the emergence of antibiotic resistance are causing a real public health problem Antibiotics-based treatments result in the destruction of commensal bacteria and drug resistance Newer antibiotics are kept as last resort therapy THERAPEUTIC APPROACH: Antibiotics versus virulence inhibitors Common ground in both approaches: Infections are treated through eradication of bacteria in the blood. Advantages of virulence inhibitors: Virulence inhibitors do not perturb development of commensal bacteria. Diminished risk of developing resistant mutants because of